share_log
Moomoo 24/7 ·  Apr 17 09:00
ABVC Biopharma Executes a Global Licensing Definitive Agreement for the Treatment of Nsclc, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment